Friday, June 19, 2026

pharma · Metastatic Colorectal Cancer · Duchenne Muscular Dystrophy · SMMT

Summit Therapeutics

Summit Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

601 Brickell Key Dr, Suite 1000, Miami, Florida 33131, US HQ
2003 Founded
367 Employees
Public company Type
SMMT · NYSE Ticker
Company details
Intelligence · Clinical Programs

Summit Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Summit Therapeutics.

Summit Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Replens and coconut oil

    Summit Therapeutics

    Genitourinary Abnormality

    phase 1 other terminated

    1 trial
  2. SMT C1100

    Summit Therapeutics

    Duchenne Muscular Dystrophy

    phase 1 small molecule completed

    1 trial
  3. SMT C1100

    Summit Therapeutics

    Muscular Dystrophy, Duchenne

    phase 1 small molecule completed

    1 trial
  4. ketamine

    Summit Therapeutics

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Summit Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.